The third domestic company, Qilu Eltrodopal ethanolamine generic drug production
With the coming Oil & Gas Asia Exhibition in Pakistan, ECHEMI rolls out a new bulk purchasing activity for its new and old customers. This activity will be valid before March 16 when the exhibition come to the end. The more you buy, the more money you will save.
How to join this bulk purchasing?
You can enjoy the most favorable prices via three steps:
First, you should come to the home page of ECHEMI, then you can see the the following page:
Second, input your demand and submit the inquiry.
Third, ECHEMI will give you a reply within 1 working day after receiving your inquiry.
Opportunity knocks but once! Come on, seize this opportunity right now!
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-07-12
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
FDA Names Veteran Oncology Regulator Pazdur as Director of Drug Review Center
-
Pfizer Warns Germany: Drug Pricing Could Put Investment at Risk
-
J&J VAT Dispute Threatens Free Medicine Access in Britain
-
FDA Clears Sanofi’s Wayrilz (rilzabrutinib) for Adult ITP; U.S. Launch in September
-
Aficamten Beats Metoprolol in Obstructive HCM, Strengthening Case Ahead of FDA Decision
-
AstraZeneca Targets Year-End Filing for Novel Hypertension Drug Baxdrostat
-
Reducing to Refocus: Novo Nordisk’s 9,000-Job Cut and the Strategic Realignment in Pharma
-
Hengrui Strikes $500 Million Global Drug Deal with GSK Potential Payouts Up to $12 Billion
-
Torrent Pharma Targets First Wave Semaglutide Launch Revenue Up 11 Percent as Patent Ends
-
Lilly’s U.S. API Investment Highlights a New Phase of Pharma Supply Localization
Recommend Reading
-
Platinum Chemotherapy Shortages Expose the Fragility of Essential API Supply
-
Lilly Bets Bigger on China
-
Rising API Costs Threaten Drug Prices
-
BioNTech’s Founders Turn the Page
-
India’s API Trade Balance Turns Positive
-
This Week's Anhydrous Hydrogen Fluoride Market Prices Stabilize in China (9.15-9.19)
-
This Week's TDI Market Decline Slows Down (9.15-9.19)
-
This Week's Styrene Market Fluctuates and Rises (9.15-9.19) in China
-
This week, the Chinese hydrofluoric acid market mainly operated with consolidation (6.15-6.18)
-
Insufficient Positive Factors, Shandong Cyclohexanone Market Trending Downward